- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03904238
Psychosocial Adjunctive Treatment for Hypersomnia (PATH)
Psychosocial Adjunctive Treatment for Hypersomnia (PATH): A Pilot Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Chronic hypersomnia (CH) is a serious and debilitating condition involving persistent excessive daytime sleepiness (EDS) and includes narcolepsy and idiopathic hypersomnia (IH). Currently, pharmacotherapy is the only empirically-validated treatment for reducing EDS in this patient population but the burden of long-term management and adverse effects of the medication lead to poor health-related quality of life (HRQoL) and elevations in depressive symptoms
Evidence-based psychosocial interventions have been developed in other areas to improve HRQoL related to chronic illnesses, such as cancer and chronic pain. These interventions typically involve a package of cognitive and behavioral techniques teaching coping skills (e.g., emotion-focused and problem-focused coping), behavioral management of the chronic illness symptoms (e.g., relaxation for pain management), and other strategies to improve psychosocial functioning (e.g., mindfulness). However, no such interventions have been developed or used for people with CH. Therefore, a major research gap exists for an empirically-validated psychosocial intervention which is aimed directly at improving emotional functioning and HRQoL for people with CH.
The purpose of this project is to develop a cognitive-behavioral treatment for hypersomnia (CBT-H) and conducting a feasibility trial of CBT-H. The specific aims for this project are to: 1) develop and refine a treatment protocol for CBT-H; 2) identify the optimal delivery format of CBT-H; and 3) gather feasibility data on recruitment, retention, and selection criteria for a future clinical trial. The overall significance of this project is to improve the quality of care for people with CH by using a psychosocial intervention with medical management of hypersomnia.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Center for Circadian and Sleep Medicine, Northwestern University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males and females age 18 and older.
- Meets criteria for Narcolepsy (Type I or II) or Idiopathic Hypersomnia (IH).
- Moderate to severe symptoms of depression.
- Established standard care for CH at a sleep clinic.
Exclusion Criteria:
- Hypersomnia not of central origin.
- Current suicidal ideation or intent.
- Uncontrolled medical conditions or physical limitations that require immediate medical treatment that would prevent ability to engage in the treatment protocol.
- Inability to engage in the treatment protocol due to a psychiatric or cognitive issue.
- Untreated moderate-to-severe sleep-related breathing disorder.
- Unable to attend intervention sessions due to accessibility or availability.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CBT-H (Individual format)
Individual CBT-H consists of 6 weekly sessions that are conducted one-on-one with a study therapist using live videoconferencing or in-person.
Each session is expected to last about 45 to 60 minutes.
|
The CBT-H intervention consists of 6 weekly sessions that are conducted either individually or in small groups.
Each session is expected to last about 45 to 60 minutes and will be delivered a study therapist using live videoconferencing or in-person.
The treatment package consists of cognitive and behavioral modules that include education about hypersomnia, coping skills training, emotion regulation regarding the perceived limitations of living with chronic hypersomnia (e.g., "I cannot live a full life because of my illness"), and behavioral techniques using scheduled naps, sleep hygiene, and regularizing sleep schedules at night which are on the current optional recommendations for hypersomnia.
|
Experimental: CBT-H (Group format)
Group-based CBT-H consists of 6 weekly sessions that are conducted in groups with a study therapist using live videoconferencing or in-person.
Each session is expected to last about 45 to 60 minutes.
The treatment package consists of the same cognitive and behavioral modules as the individual CBT-H.
However, participants are also provided the opportunity to share their experiences and provide peer support in the group format.
|
The CBT-H intervention consists of 6 weekly sessions that are conducted either individually or in small groups.
Each session is expected to last about 45 to 60 minutes and will be delivered a study therapist using live videoconferencing or in-person.
The treatment package consists of cognitive and behavioral modules that include education about hypersomnia, coping skills training, emotion regulation regarding the perceived limitations of living with chronic hypersomnia (e.g., "I cannot live a full life because of my illness"), and behavioral techniques using scheduled naps, sleep hygiene, and regularizing sleep schedules at night which are on the current optional recommendations for hypersomnia.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient Health Questionnaire (PHQ)
Time Frame: Change from Baseline PHQ at 6 weeks (Post-treatment)
|
The PHQ is a 9-item self-report scale of depressive symptoms that has been validated to assess the severity of depression in clinical practice.
PHQ-9 cut scores of 5, 10, 15, and 20 represented mild, moderate, moderately severe, and severe depression, respectively.
|
Change from Baseline PHQ at 6 weeks (Post-treatment)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient Reported Outcomes Measurement Information System (PROMIS) Self Efficacy Scale
Time Frame: Baseline to post-treatment (6 weeks)
|
Measures general self-efficacy, self-efficacy for managing emotions, self-efficacy for managing social interactions, self-efficacy for managing symptoms using Computer Adaptive Testing (CAT) with higher scores reflecting better self-efficacy.
|
Baseline to post-treatment (6 weeks)
|
Patient Reported Outcomes Measurement Information System (PROMIS) Depression Scale
Time Frame: Baseline to post-treatment (6 weeks)
|
Measures depressive symptoms using Computer Adaptive Testing (CAT) with higher scores reflecting more anxiety symptoms.
|
Baseline to post-treatment (6 weeks)
|
Patient Reported Outcomes Measurement Information System (PROMIS) Anxiety Scale
Time Frame: Baseline to post-treatment (6 weeks)
|
Measures anxiety symptoms using Computer Adaptive Testing (CAT) with higher scores reflecting more anxiety symptoms.
|
Baseline to post-treatment (6 weeks)
|
Patient Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance Scale
Time Frame: Baseline to post-treatment (6 weeks)
|
Measures sleep disturbances using Computer Adaptive Testing (CAT) with higher scores reflecting more sleep disturbance.
|
Baseline to post-treatment (6 weeks)
|
Patient Reported Outcomes Measurement Information System (PROMIS) Sleep-Related Impairment Scale
Time Frame: Baseline to post-treatment (6 weeks)
|
Measures sleep-related impairment using Computer Adaptive Testing (CAT) with higher scores reflecting worse outcomes.
|
Baseline to post-treatment (6 weeks)
|
Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Scale
Time Frame: Baseline to post-treatment (6 weeks)
|
Measures fatigue using Computer Adaptive Testing (CAT) with higher scores reflecting worse outcomes.
|
Baseline to post-treatment (6 weeks)
|
Patient Reported Outcomes Measurement Information System (PROMIS) Phyiscal Function Scale
Time Frame: Baseline to post-treatment (6 weeks)
|
Measures physical function using Computer Adaptive Testing (CAT) with higher scores reflecting better physical function.
|
Baseline to post-treatment (6 weeks)
|
Epworth Sleepiness Scale (ESS)
Time Frame: Baseline to post-treatment (6 weeks)
|
The ESS consists of eight questions rated from 0 to 3, with higher scores indicating greater likelihood of falling asleep.
Total scores of 10 or greater reflect excessive daytime sleepiness.
|
Baseline to post-treatment (6 weeks)
|
Functional Outcomes of Sleep Questionaire (FOSQ)
Time Frame: Baseline to post-treatment (6 weeks)
|
The FOSQ assesses the impact of sleepiness on daily behaviors and quality of life.
It is comprised of 30 items divided into five subscales: activity level, vigilance, intimate and sexual relationships, general productivity, and social outcome.
Items are rated from 1 to 4, with higher score reflecting better functioning.
|
Baseline to post-treatment (6 weeks)
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STU00207253
- 185-SR-17 (Other Grant/Funding Number: American Academy of Sleep Medicine Foundation)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Narcolepsy
-
University of Dublin, Trinity CollegeSt. James's Hospital, IrelandSuspendedNarcolepsy | Hypersomnolence | Narcolepsy Type 1 | Narcolepsy Without Cataplexy | Narcolepsy With Cataplexy | Narcolepsy 1 | Narcolepsy and HypersomniaIreland
-
Northwestern UniversityActive, not recruitingNarcolepsy | Narcolepsy Type 1 | Narcolepsy Without Cataplexy | Narcolepsy With Cataplexy | Narcolepsy Type 2United States
-
NLS PharmaceuticsCompletedNarcolepsy | Narcolepsy Without Cataplexy | Narcolepsy With CataplexyUnited States
-
Boston Children's HospitalAmerican Academy of Sleep MedicineNot yet recruitingIdiopathic Hypersomnia | Narcolepsy Type 1 | Narcolepsy Type 2United States
-
NLS PharmaceuticsNot yet recruitingNarcolepsy Type 1 | Narcolepsy With Cataplexy
-
TakedaRecruitingNarcolepsy Type 1 | Narcolepsy Type 2Spain, Germany, United States, Italy, Netherlands, Japan, France, Norway, Australia, Finland, Switzerland, Sweden
-
Northwestern UniversityNational Center for Complementary and Integrative Health (NCCIH)CompletedNarcolepsy | Narcolepsy Without Cataplexy | Narcolepsy With CataplexyUnited States
-
BioprojetActive, not recruitingNarcolepsy Without Cataplexy | Narcolepsy With CataplexyFrance, Italy, Russian Federation, Finland, Netherlands
-
TakedaTerminatedNarcolepsy Type 1 (NT1) | Narcolepsy Type 2 (NT2)China, United States, Korea, Republic of, France, Italy, Finland, Spain, Czechia, Canada, Japan, Hungary, Netherlands
-
Emory UniversityNational Institute of Neurological Disorders and Stroke (NINDS)RecruitingIdiopathic Hypersomnia | Narcolepsy Without Cataplexy | Narcolepsy With CataplexyUnited States
Clinical Trials on Cognitive-Behavior Therapy for Hypersomnia (CBT-H)
-
University of California, San DiegoNational Institute of Mental Health (NIMH)CompletedAnxiety Disorders | Generalized Anxiety Disorder | Panic Disorder
-
Walter Reed National Military Medical CenterUniformed Services University of the Health SciencesTerminatedInsomnia | Cardiovascular Risk FactorUnited States
-
University of South FloridaRecruitingDementia | Insomnia ChronicUnited States
-
Baylor College of MedicineSouth Central VA Mental Illness Research, Education & Clinical CenterCompletedDepression | AnxietyUnited States
-
Duke UniversityRecruitingInsomnia | Posttraumatic Stress Disorder | Cardiovascular Risk FactorUnited States
-
University of WashingtonKaiser PermanenteUnknown
-
Karolinska InstitutetUppsala UniversityCompleted
-
Ohio State University Comprehensive Cancer CenterCompletedMajor Depressive DisorderUnited States
-
Mayo ClinicRecruitingMalignant Solid Neoplasm | Hematopoietic and Lymphoid System NeoplasmUnited States
-
VA Office of Research and DevelopmentVA Maryland Health Care SystemRecruitingPsychotic Disorders | Schizophrenia | Chronic Pain | Bipolar Disorder | Affective Disorders, PsychoticUnited States